Profile picture

Professor Mauro Giacca

King's College London, London (United Kingdom of Great Britain & Northern Ireland)
Membership: ESC Professional Member
Follow
Biography
Mauro Giacca, MD PhD, is Head of the School of Cardiovascular and Metabolic Medicine&Sciences at King’s College London. Until 2019, he has served as Director-General of the ICGEB, a United Nations organization. Since 2005, he is Full Professor of Molecular Biology at the University of Trieste, Italy. Prof Giacca is considered an expert in gene and RNA therapy for cardiovascular disorders. He leads a recently established MRC/BHF Centre for Cardiac Repair and Regeneration (REACT) and is Co-Director of the BHF Centre of Research Excellence at King’s. His research is funded internationally, including three consecutive ERC Advanced grants and 2 consecutive Leducq Foundation grants, and a BHF Programme grant. Prof Giacca is a Fellow of the Academy of Medical Sciences, UK and is the past-president of the International Society for Heart Research (ISHR)-ES. He is the founder of Forcefield Therapeutics and Heqet Therapeutics, which develop biologics for myocardial infarction and heart failure.
Logo ESC

Contributor content

Module A: Models and new technologies - Translational studies using human samples myocardial slices?
Session
Module A: Models and new technologies - Translational studies using human samples myocardial slices?
14 June 2026
Advances in gene therapy and gene editing in the heart and vasculature
Session
Advances in gene therapy and gene editing in the heart and vasculature
31 August 2025
Molecular mechanisms and therapeutic targets in cardiomyopathy
Session
Molecular mechanisms and therapeutic targets in cardiomyopathy
31 August 2025
Vascular and immune control of organ function
Session
Vascular and immune control of organ function
2 September 2024
Basic and Translational Late-Breaking Science
Session
Basic and Translational Late-Breaking Science
1 September 2024
Hot papers in genes and gene editing in heart failure
Session
Hot papers in genes and gene editing in heart failure
26 August 2023
RNA and gene therapy of vascular diseases
Session
RNA and gene therapy of vascular diseases
29 August 2022
CRISPR/Cas9 gene editing for heart disease: ready for prime time?
Session
CRISPR/Cas9 gene editing for heart disease: ready for prime time?
29 August 2021
Young Investigator Awards Session in Basic Science
Session
Young Investigator Awards Session in Basic Science
29 August 2021
The dynamic epigenome - Programming the cardiac myocyte in development, health and disease.
Session
The dynamic epigenome - Programming the cardiac myocyte in development, health and disease.
21 April 2018

ESC 365 is supported by